The ADCS, the leading Alzheimer’s disease academic consortium, funded by the USA National Institute of Aging at the National Institutes of Health, has selected Mindset’s lead drug candidate, OXIGONŽ for an ADCS sponsored clinical trial.
The Britain-Israel Technology Foundation (Britech) Foundation, Ltd.
Britech identified the potential in PRO-TAMAD, a joint venture between Mindset and Proteome Sciences PLC. This Britech funded project is a unique and powerful partnership for drug discovery and diagnostic markers in Alzheimer’s disease.
The ISOA, one of the largest private sources of international philanthropic funding for drug discovery in cognitive aging and Alzheimer's disease, is providing financial support for key aspects of pre-clinical and early stage clinical testing of Mindset’s Drug candidate, OXIGONŽ.
The Israel-USA Binational Research & Development (BIRD) Foundation
The NIA recognized the promise of OXIGONŽ in Alzheimer’s disease, and is providing directed support to critical elements of the pre-clinical development program.
